BridgeBio Pharma Inc (NAS:BBIO)
$ 27.94 0.18 (0.65%) Market Cap: 5.23 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

BridgeBio Pharma Inc to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)- Conference Call Transcript

Mar 14, 2022 / 12:00PM GMT
Release Date Price: $8.25 (-3.85%)
Operator

Good day, and thank you for standing by. Welcome to the BridgeBio Pharma to discuss Phase II data for BBP-418 in limb-girdle muscular dystrophy Type 2i conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) And now I would like to hand the conference over to Mr. Neil Kumar, CEO of BridgeBio Pharma. Thank you. Please go ahead, sir.

Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, President, CEO & Director

Well, thank you so much, operator, and thanks, everyone, for joining us as we discuss some exciting new data from our program targeting the disease, the large and devastating to the limb-girdle muscular dystrophy Type 2i. Before we begin, I just want to make a quick reminder. We'll be making some forward-looking statements today, which are based on our current expectations and beliefs. As such, these statements are subject to certain risks and uncertainties, and I'd encourage everyone, as you know, to consult the section entitled Risk Factors in our most recent annual report on Form 10-K

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot